Similar articles

• Letrozole after tamoxifen for breast cancer--what is the price of success?

  Bryant J, Wolmark N. Bryant J, et al. N Engl J Med. 2003 Nov 6;349(19):1855-7. doi: 10.1056/NEJMe038167. Epub 2003 Oct 9. N Engl J Med. 2003. PMID: 14551339 No abstract available.
• [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].

  Forciniti S. Forciniti S. Suppl Tumori. 2004 Jul-Aug;3(4):S25-6. Suppl Tumori. 2004. PMID: 15206205 Clinical Trial. Italian. No abstract available.
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. Goss PE, et al. N Engl J Med. 2003 Nov 6;349(19):1793-802. doi: 10.1056/NEJMoa032312. Epub 2003 Oct 9. N Engl J Med. 2003. PMID: 14551341 Clinical Trial.
• Anti-tumor effects of letrozole.

  Miller WR, Anderson TJ, Dixon JM. Miller WR, et al. Cancer Invest. 2002;20 Suppl 2:15-21. doi: 10.1081/cnv-120014882. Cancer Invest. 2002. PMID: 12442345 Review.
• [Endocrine therapy of causation: role of aromatase inhibitors in breast cancer].

  Longo F, Mansueto G. Longo F, et al. Tumori. 2003 Nov-Dec;89(6):21-8. doi: 10.1177/030089160308900622. Tumori. 2003. PMID: 14870836 Review. Italian. No abstract available.